Aurobindo Pharma Limited has announced a share buyback program for up to 54,23,728 fully paid-up equity shares at a price of ₹1,475 per share. The total value of the buyback is set at ₹800 crore. The buyback will be conducted through the tender offer route on a proportionate basis. The buyback window opens on April 23, 2026, and concludes on April 29, 2026.
Buyback Details and Pricing
Aurobindo Pharma Limited has officially declared a share buyback initiative, targeting up to 54,23,728 equity shares. This represents approximately 0.93% of the company’s total outstanding equity. The shares will be acquired at a price of ₹1,475 per share, resulting in a total aggregate outlay not exceeding ₹800 crore. This strategic capital allocation is being executed to reward shareholders and improve key financial metrics such as return on equity and earnings per share.
Key Buyback Schedule
The buyback program will take place over a short, efficient timeframe. The schedule for the tender offer is as follows:
- Buyback Opening Date: April 23, 2026
- Buyback Closing Date: April 29, 2026
- Last Date for Tender Form Receipt: April 29, 2026
- Final Settlement of Bids: May 7, 2026
Shareholder Participation
The buyback is open to all eligible shareholders who held equity shares as of the record date, April 17, 2026. The process will be conducted using the tender offer route via the stock exchange mechanism. A portion of the shares is reserved for small shareholders, defined as those whose holdings had a market value of not more than ₹2,00,000 as of the record date. Participants should ensure their demat and bank accounts are active to receive payouts and for the handling of unaccepted shares.
Source: BSE
